Safety of a Maintenance Therapy With Lenalidomide After Reduced-intensity Allogeneic Stem Cell Transplantation for Chemosensitive Relapsed Multiple Myeloma.

Trial Profile

Safety of a Maintenance Therapy With Lenalidomide After Reduced-intensity Allogeneic Stem Cell Transplantation for Chemosensitive Relapsed Multiple Myeloma.

Completed
Phase of Trial: Phase I

Latest Information Update: 24 Jul 2015

At a glance

  • Drugs Lenalidomide (Primary)
  • Indications Graft-versus-host disease; Multiple myeloma
  • Focus Adverse reactions
  • Acronyms REVALLO
  • Most Recent Events

    • 31 Jul 2013 Planned end date changed from 1 Aug 2014 to 1 Aug 2015 as reported by ClinicalTrials.gov.
    • 29 Aug 2011 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
    • 25 Aug 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top